Prelude Announces Presentations at 2025 AACR Annual Meeting
Provided By GlobeNewswire
Last update: Apr 25, 2025
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development
Read more at globenewswire.comNASDAQ:PRLD (11/21/2025, 12:28:57 PM)
1.595
-0.01 (-0.31%)
Find more stocks in the Stock Screener
PRLD Latest News and Analysis
9 days ago - By: Chartmill
